Analysts Set Repligen Corporation (NASDAQ:RGEN) Target Price at $169.45

Key Points

• Repligen Corporation has received a consensus recommendation of "Moderate Buy" from twelve brokerages, with four analysts suggesting a hold and eight recommending a buy.
• The average one-year target price for Repligen's stock among analysts is $169.45, with notable upgrades and varying target prices from different firms.
• Despite missing earnings expectations for the last quarter, Repligen reported a 14.8% increase in revenue compared to the same period last year, amounting to $182.37 million.

Shares of Repligen Corporation (NASDAQ:RGEN - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve analysts that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $169.45.

A number of research firms have commented on RGEN. Wells Fargo & Company lowered their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a report on Tuesday, April 29th. HC Wainwright reiterated a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Monday, May 5th. Stephens upgraded Repligen to an "overweight" rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. Finally, Wall Street Zen downgraded Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th.

Repligen Trading Up 1.6%

Shares of NASDAQ RGEN traded up $1.84 during midday trading on Thursday, reaching $118.91. The company had a trading volume of 941,488 shares, compared to its average volume of 783,381. Repligen has a one year low of $102.96 and a one year high of $182.52. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. The firm's fifty day moving average price is $123.39 and its 200-day moving average price is $136.49. The stock has a market cap of $6.68 billion, a PE ratio of -475.62, a price-to-earnings-growth ratio of 2.27 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.65%. The company's revenue was up 14.8% on a year-over-year basis. During the same period last year, the firm posted $0.40 EPS. On average, equities research analysts anticipate that Repligen will post 1.72 earnings per share for the current year.

Institutional Trading of Repligen

Several institutional investors have recently added to or reduced their stakes in RGEN. Raiffeisen Bank International AG purchased a new stake in Repligen during the 4th quarter valued at $29,000. Twin Tree Management LP purchased a new stake in Repligen during the 1st quarter valued at $29,000. Itau Unibanco Holding S.A. purchased a new stake in Repligen during the 4th quarter valued at $40,000. Signaturefd LLC boosted its stake in Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 128 shares during the last quarter. Finally, Center for Financial Planning Inc. lifted its holdings in shares of Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after buying an additional 193 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.